Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Fenebrutinib targets cells in the immune system known as B cells and microglia
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Subscribe To Our Newsletter & Stay Updated